drugset / Trial / NCT02689726
Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-08
- Completion
- 2016-08
Outcome
Outcome not reported
Stopped: “Lack of efficacy in European Phase 2 study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GTL001 | Vaccine | — | — |
| Background | Imiquimod | Other / unclassified | 5 % | Topical |
Indications
No indication recorded.